Kewaunee Scientific Reports Strong Sales Growth, Repays $23M in Seller Notes
Summary
Kewaunee Scientific filed its annual 10-K, reporting a 17.3% increase in fiscal year 2026 sales to $282.0 million and a significant repayment of $23.0 million in seller notes, despite a decline in net earnings.
Key Events
-
Fiscal Year 2026 Sales Growth
Net sales increased 17.3% to $282.0 million for fiscal year 2026, up from $240.5 million in the prior year.
-
Net Earnings Decline
Net earnings decreased to $9.6 million ($3.22 diluted EPS) in fiscal year 2026 from $11.4 million ($3.83 diluted EPS) in fiscal year 2025, primarily due to increased operating expenses and interest related to the Nu Aire acquisition.
-
Significant Debt Reduction
The company repaid $23.0 million in subordinated seller notes, substantially reducing its total long-term debt from $37.7 million to $20.1 million.
-
Improved Operating Cash Flow
Cash provided by operating activities increased to $18.6 million in fiscal year 2026 from $14.8 million in the prior year.
Analysis
This annual report provides a comprehensive overview of Kewaunee Scientific's fiscal year 2026 performance. While net earnings decreased, the company achieved substantial sales growth and significantly strengthened its balance sheet by repaying $23.0 million in seller notes related to the Nu Aire acquisition. This debt reduction improves the company's financial stability and liquidity, which is a key positive for a company of this size. The filing also details increased operating cash flow and compliance with debt covenants, providing a clearer picture of its financial health.
At the time of this filing, KEQU was trading at $35.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $102.7M. The 52-week trading range was $33.27 to $60.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.